TrialCurveXELOX + bevacizumab ± adoptive cell immunotherapy in colorectal cancer: reconstructed Kaplan–Meier curves
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Signal Transduct Target Ther. 2024 Apr 3;9:79. doi: 10.1038/s41392-024-01788-2 |
|---|---|
| DOI | 10.1038/s41392-024-01788-2 |
| Registry | NCT03950154 |
| Phase | Phase 3 |
| Conditions | Colorectal Cancer |
| Interventions | Bevacizumab Injection [Avastin], Oxaliplatin, Capecitabine, PD1-T cells |
| Sponsor | Tianjin Medical University Cancer Institute and Hospital |
| Enrolment | 198 |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival — Intention-to-treat population
From figure panel a · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Immunotherapy group 14.7 months; Control group 9.8 months. Survival at 12 months: Immunotherapy group 56%; Control group 36%. Hazard ratio Immunotherapy group vs Control group 0.59 (95% CI 0.40–0.86).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Immunotherapy group | 100 | 50 | 14.7 |
| Control group | 102 | 59 | 9.8 |
- Immunotherapy group vs Control group: reconstructed HR 0.59 (95% CI 0.40–0.86)
Landmark survival (reconstructed)
| Time | Immunotherapy group | Control group |
|---|---|---|
| 6 mo | 85.0% | 83.4% |
| 12 mo | 56.1% | 35.9% |
| 18 mo | 40.5% | 24.8% |
| 24 mo | 29.9% | 15.0% |
| 36 mo | 12.5% | — |
Checks against the published figure
- Immunotherapy group median: printed 14.8, reconstructed 14.7 pass
- Control group median: printed 9.9, reconstructed 9.83 pass
- hazard ratio (direction inferred): printed 0.6, reconstructed 0.587 pass
Overall survival — Intention-to-treat population
From figure panel b · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Immunotherapy group not reached; Control group 27.4 months. Survival at 12 months: Immunotherapy group 84%; Control group 80%. Hazard ratio Immunotherapy group vs Control group 0.55 (95% CI 0.32–0.95).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Immunotherapy group | 100 | 21 | not reached |
| Control group | 102 | 35 | 27.4 |
- Immunotherapy group vs Control group: reconstructed HR 0.55 (95% CI 0.32–0.95)
Landmark survival (reconstructed)
| Time | Immunotherapy group | Control group |
|---|---|---|
| 6 mo | 95.9% | 93.7% |
| 12 mo | 84.1% | 79.6% |
| 18 mo | 75.2% | 62.3% |
| 24 mo | 72.4% | 55.6% |
| 36 mo | 72.4% | 44.2% |
Checks against the published figure
- Control group median: printed 25.6, reconstructed 27.4 pass
- hazard ratio (direction inferred): printed 0.57, reconstructed 0.551 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- BREAKWATER: Overall survival
- Cetuximab β + FOLFIRI in RAS/BRAF wild-type colorectal cancer: Overall survival; Progression-free survival (BIRC-assessed)
- SCOT: Disease-free survival; Overall survival; Survival after recurrence (SAR)
- Sequential vs upfront oxaliplatin in metastatic colorectal cancer: Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials